HAS or JOUT or OSW

Key Takeaways

• Johnson Outdoors (HAS) and Johnson Outdoors (JOUT) are the same company; the ticker HAS represents its Class A common stock, while JOUT is its Class B common stock. Both share the same fundamentals and recent performance.
• Ostara Therapeutics (OSW) operates in the biotechnology sector, delivering a stark contrast in revenue scale, volatility, and growth drivers compared with the outdoor‑recreation business of Johnson Outdoors.
• In FY 2024, Johnson Outdoors logged $592.8 M in net sales but posted a net loss of $26.5 M, driven by a $11.2 M goodwill impairment in the Fishing segment.
• Ostara’s FY 2024 revenue remained under $5 M, but the company posted a net loss of $71.1 M as it advanced its lead‑candidate OSW‑1 in clinical trials.
• Currency exposure (≈14 % of Johnson Outdoors’ revenue) and seasonal demand create earnings volatility, while Ostara’s results are highly dependent on clinical trial outcomes and regulatory milestones.

Introduction

This comparison focuses on three publicly traded symbols—HAS, JOUT, and OSW. While HAS and JOUT represent two share classes of Johnson Outdoors (a global outdoor‑recreation products maker), OSW is Ostara Therapeutics, a clinical‑stage biotech firm developing novel antibody‑drug conjugates. Traders and investors looking for exposure to consumer discretionary versus high‑risk biotech will find this side‑by‑side analysis useful.

HAS Overview and Recent Performance

Johnson Outdoors designs, manufactures, and markets seasonal recreation products under brands such as Minn Kota, Humminbird, Cannon, Jetboil, Old Town, and SCUBAPRO. The company reports its results in four operating segments: Fishing, Camping, Watercraft Recreation, and Diving. In FY 2024 net sales fell 11 % to $592.8 M, with the Fishing segment (the largest contributor) dropping $40.6 M due to weaker consumer discretionary spending and intensified competition from brands like Lowrance and Garmin. Gross margin compressed to 33.9 % (down from 36.8 % in FY 2023) because lower sales reduced overhead absorption. A $11.2 M goodwill impairment in the Fishing reporting unit drove operating loss to $43.5 M. Despite the loss, cash from operating activities remained positive at $41.0 M, reflecting disciplined inventory management. The company continues to distribute a quarterly cash dividend of $1.32 per Class A share, with the Board reviewing payouts each quarter.

JOUT Overview and Recent Performance

Class B shares (JOUT) are convertible into Class A shares at a 1:1 ratio and carry ten votes per share. Financially, JOUT mirrors HAS because both classes represent the same equity. Consequently, the same FY 2024 figures—$592.8 M sales, $26.5 M net loss, and a $11.2 M goodwill charge—apply. The key difference lies in voting rights and liquidity; JOUT’s float is thin (≈5.3 M shares), leading to higher price volatility compared with HAS.

OSW Overview and Recent Performance

Ostara Therapeutics (OSW) is a clinical‑stage biotechnology company focused on antibody‑drug conjugates (ADCs) for cancer treatment. The firm’s lead program, OSW‑1, targets HER2‑expressing tumors, and a second‑generation candidate entered Phase 1/2 in early 2024. Revenue is primarily from collaboration agreements and non‑recurring licensing fees, totaling $4.7 M in FY 2024. Operating expenses surged to $76.1 M, reflecting R&D spend, trial costs, and increased SG&A. The result was a net loss of $71.1 M, driven largely by stock‑based compensation and accrued clinical expenses. OSW’s cash position declined to $165 M after financing activities, but the company retains sufficient runway to fund its trial programs into 2026. The stock is highly sensitive to trial readouts and regulatory milestones.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated set of hundreds of AI‑driven trading bots that scan thousands of tickers. Each bot applies a distinct strategy—ranging from momentum and mean‑reversion to multi‑timeframe trend following—and reports performance metrics such as win‑rate, Sharpe ratio, and maximum drawdown. Only the bots demonstrating robust risk‑adjusted returns in the current market environment earn a spot in the “Trending” list, which typically features 20‑30 bots at any time. Traders can explore each bot’s back‑tested and live performance before deciding which aligns with their risk tolerance.

Head-to-Head Comparison

• Industry & Business Model: HAS/JOUT – consumer discretionary outdoor equipment; OSW – biotech R&D with no product sales.
• Revenue Scale: HAS/JOUT generated $592.8 M in FY 2024; OSW less than $5 M.
• Growth Drivers: Seasonal demand, new product launches, and brand extensions for HAS/JOUT; clinical trial milestones and partnership funding for OSW.
• Profitability: HAS/JOUT posted a net loss of $26.5 M (loss per diluted share $2.60); OSW’s loss was $71.1 M (loss per diluted share $7.07).
• Margin Sensitivity: HAS/JOUT margins fluctuate with inventory levels, foreign‑currency translation (≈14 % of revenue), and warranty/return reserves. OSW margins are driven by R&D spend and one‑off licensing revenue.
• Risk Factors: Seasonal consumer spending, competitive pressure, and goodwill impairment for Johnson Outdoors; clinical‑trial failure risk, regulatory uncertainty, and high cash burn for Ostara.
• Liquidity & Cash Flow: HAS/JOUT produced $41.0 M operating cash in FY 2024; OSW’s operating cash was negative, relying on financing activities.
• Share Structure & Volatility: HAS (Class A) has higher float and lower volatility; JOUT (Class B) is thinly traded with higher price swings. OSW’s stock is intrinsically volatile due to biotech catalyst‑driven moves.
• Valuation Sensitivity: Johnson Outdoors valuation hinges on comparable consumer discretionary multiples (EV/EBITDA, P/S). Ostara valuation is heavily weighted to forward‑looking risk‑adjusted metrics such as price‑to‑sales (often >30×) and probability‑weighted NPV of pipeline assets.

Tickeron AI Verdict

Based on observable market signals, Tickeron’s AI currently favors the **HAS/JOUT** share class with the higher float (Class A) for most traders. The reasons are:

• Consistent cash generation despite a recent loss, providing dividend sustainability.
• Seasonally driven but predictable revenue streams across four diversified product lines.
• Lower volatility relative to the thinly traded JOUT and significantly lower risk compared with OSW’s binary trial outcomes.
• The AI’s trend‑strength algorithm shows a modest upward bias for HAS over the past 12 weeks, whereas OSW exhibits high upside potential only under a positive trial catalyst, which the model flags as high‑risk.

Thus, for investors seeking steady dividend income and modest upside, the AI leans toward **HAS** (Class A). Risk‑tolerant speculators may still monitor OSW for breakthrough data that could trigger sharp price appreciation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations